Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Name: Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Published: 2022
License: Public Domain

National Cancer Institute (NCI) · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

advanced extrapulmonary neuroendocrine carcinoma, metastatic extrapulmonary neuroendocrine carcinoma, recurrent extrapulmonary neuroendocrine carcinoma, unresectable extrapulmonary neuroendocrine carcinoma, interventional, phase2, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Related documents